keyword
https://read.qxmd.com/read/37655597/impact-of-daratumumab-on-stem-cell-mobilization-and-collection-engraftment-and-early-post-transplant-complications-among-multiple-myeloma-patients-undergoing-autologous-stem-cell-transplantation
#21
JOURNAL ARTICLE
Evangelos Eleutherakis Papaiakovou, Evangelos Terpos, Nikolaos Kanellias, Magdalini Migkou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Despoina Fotiou, Panagiotis Malandrakis, Foteini Theodorakakou, Vasiliki Spiliopoulou, Ioannis V Kostopoulos, Ourania Tsitsiloni, Panagiotis Tsirigotis, Meletios-Athanasios Dimopoulos, Efstathios Kastritis
Autologous stem cell transplantation (ASCT) remains a standard therapy for multiple myeloma (MM) patients. Our study aimed to assess the impact of daratumumab-containing induction on stem cell (SC) mobilization, apheresis and hospitalization. We evaluated 200 newly diagnosed MM patients that were mobilized for SC collection and which received induction with ( N  = 40) or without daratumumab ( N  = 160). Dara group patients required more frequent use of plerixafor, larger collection volumes, and had lower SC yield...
December 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37635081/feasibility-of-peripheral-blood-stem-cell-collection-from-sickle-cell-trait-donors-with-an-intensified-g-csf-regimen
#22
JOURNAL ARTICLE
Morad Mohrez, Anja Troeger, Katharina Kleinschmidt, Tarek Hanafee Alali, Marcus Jakob, Andreas Brosig, Viola Hähnel, Silke Kietz, Robert Offner, Ralph Burkhardt, Selim Corbacioglu, Norbert Ahrens, Juergen Foell
OBJECTIVES: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCD and bone marrow from an HLA-matched sibling is currently the standard of care. Haploidentical HSCT from a family donor with a TCR αβ/CD19 depleted graft (T-haplo) is an increasingly successful alternative, which requires the generation of G-CSF stimulated peripheral stem cell (PBSC) from haploidentical relatives. These sickle cell trait (SCT) donors reported to develop SCD-related complications in conditions of severe stress...
August 27, 2023: European Journal of Haematology
https://read.qxmd.com/read/37599155/the-enhanced-direct-antiglobulin-test-in-current-practice-has-a-limited-impact-on-management-of-adult-patients
#23
JOURNAL ARTICLE
Mamie Thant, Jose Cancelas, Alesia Kaplan
INTRODUCTION: The direct antiglobulin test (DAT) identifies immunoglobulin IgG and/or complement onthe red blood cell surface, allowing discrimination between immune and non-immunehemolysis. When the DAT is negative but there is clinical suspicion for immunehemolysis, an enhanced DAT can be sent to an immunohematology referencelaboratory (IRL). METHODOLOGY: This retrospective study assessed the volume of enhanced DATs at a large tertiarycare center and evaluated their impact on patient care...
August 17, 2023: Transfusion and Apheresis Science
https://read.qxmd.com/read/37560907/navigating-the-neutropenic-abyss-with-granulocyte-transfusions-retrospective-single-center-analysis-of-effectiveness-and-safety-in-india
#24
JOURNAL ARTICLE
Priti Desai, Anisha Navkudkar, Bhausaheb Bagal, Chetan Dhamne, Hasmukh Jain, Manju Sengar, Girish Chinnaswamy, Lingaraj Nayak
BACKGROUND: Hemato-oncologic patients receiving intensive chemotherapy may develop severe neutropenia and serious bacterial and/or fungal infections. Granulocyte transfusions (GTs) may be beneficial as a bridging therapy in hemato-oncologic patients with febrile neutropenia. AIM: To evaluate the clinical effectiveness of GTs in hemato-oncologic patients with febrile neutropenia. MATERIALS AND METHODS: This retrospective study evaluated the effectiveness of 150 GTs in 88 hemato-oncologic patients...
August 10, 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/37525900/apheresis-collection-of-mononuclear-cells-for-chimeric-antigen-receptor-therapies
#25
REVIEW
Robert W Maitta
Collections of lymphocytes to be genetically modified to treat hematologic malignancies have seen a dramatic increase over the last few years as commercial products have been approved. Reports of new products in development that can possibly treat solid organ malignancies represent a massive change in the field. Apheresis is at the center of the collection of cells for the manufacture of these chimeric-antigen receptor therapy products. The expansion of these collections represents one of the areas of apheresis procedures growth...
August 1, 2023: European Journal of Haematology
https://read.qxmd.com/read/37438245/collection-efficiency-in-apheresis
#26
JOURNAL ARTICLE
Yandy Marx Castillo-Aleman, Yendry Ventura-Carmenate, May Ann-Martinez
Significant advances in procedural information displayed by current apheresis machines have been made, but analyses of cell collection efficiency (CE) still rely on calculations done by apheresis professionals. Accordingly, understanding CE equations can support the optimization of apheresis techniques and identification of incidents that could impact the procedure's effectiveness. This report summarizes classical and novel CE analyses applied to apheresis exemplified by an actual case of hematopoietic progenitor cell collection...
July 5, 2023: Transfusion and Apheresis Science
https://read.qxmd.com/read/37358345/how-do-we%C3%A2-consistently-provide-high-dose-granulocyte-products-for-transfusions-in-neutropenic-patients
#27
Robert Bubar, Joseph E Kiss, Darrell J Triulzi, Pam D'Andrea, Ashley Zilich, Alesia Kaplan
BACKGROUND: The therapeutic use of granulocyte transfusions for the treatment of infections in immunocompromised patients has been a controversial practice. Randomized controlled trials suggest that benefit may be provided when a high-dose product, defined as providing a dose of at least 0.6 × 109 /kg, is offered. Here we describe the collection process and granulocyte product yield over a four-year period at a donation center supplying a large, tertiary academic medical center...
June 26, 2023: Transfusion
https://read.qxmd.com/read/37309733/favorable-recovery-profiles-and-good-reliability-among-youngest-unrelated-stem-cell-donors-supports-lowering-the-minimum-donor-registration-age
#28
JOURNAL ARTICLE
Jose Ros-Soto, Angharad Pryce, Eva Zoubek, Catherine Burlton, Richard Szydlo, Chloe Anthias
INTRODUCTION: Younger donor age in hematopoietic cell transplantation has been associated with improved overall and disease-free survival. Safety data on peripheral blood stem cell (PBSC) and bone marrow (BM) donation is well established, including in the <18-year old age group in the related setting. In response, Anthony Nolan became the first stem cell donor registry to lower the minimum age for unrelated donors to 16-years. MATERIALS AND METHODS: This retrospective study reviewed unrelated donors donating PBSC or BM for the first time between April 2015 and October 2017 since adoption of the lowered recruitment age...
June 13, 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/37304487/does-the-inclusion-of-cd34-%C3%A2-b-cell-progenitors-hematogones-in-stem-cell-enumeration-of-apheresis-product-using-ishage-protocol-affect-the-final-harvest-dose-adequacy-and-the-outcome-of-transplantation-a-single-institution-experience-from-southern-india
#29
JOURNAL ARTICLE
Naadia Fatima Nadeem, Prabhu Manivannan, Smita Kayal, Abhishekh Gowda
PURPOSE: Hematogones have similar antigenic and light scatter properties when compared to CD34+ hematopoietic stem cells (HSC) but they form a separate cluster with dimmer CD45 expression. These should be excluded while enumerating HSC, as their inclusion can overestimate and hence affect the final dose of HSC. However, their exact impact on the outcome of HSC transplant (HSCT) is not entirely known and hence this study was undertaken to address these issues, if any. METHODS: This was a retrospective study in which patients undergoing HSCT were included, and flow cytometric enumeration was done on the apheresis product using single platform ISHAGE protocol...
July 2023: Indian Journal of Hematology & Blood Transfusion
https://read.qxmd.com/read/37295970/outcomes-of-patients-after-mobilization-failure-of-hematopoietic-stem-cells-for-autologous-stem-cell-transplantation
#30
JOURNAL ARTICLE
Diego Vinicius Santinelli-Pestana, Livia Netto Chaer, Livia Mariano, Leonardo Jun Otuyama, Alfredo Medrone Junior, Vanderson Rocha
INTRODUCTION: Autologous hematopoietic stem cell transplantation (ASCT) is the long-term consolidation treatment for various hematological malignancies. The collection of hematopoietic stem cell yield is critical to successful ASCTs, but not always achieved due to hematopoietic stem cell mobilization failure (HSCMF). Details regarding the cell collection and outcomes of those who fail mobilization are still lacking. Therefore, this study aimed to yield data on clinical outcomes and cellular products after HSCMF...
June 5, 2023: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/37273319/a-vexing-problem-of-air-trapping-in-the-trima-accel-during-plateletpheresis-procedure-reflecting-our-experience-in-troubleshooting
#31
JOURNAL ARTICLE
Suman S Routray, Sukanta Tripathy, Gopal Ray
Troubleshooting for any fault of apheresis equipment or kit is hardly addressed. Here, we report a unique problem of air trapping in a kit at two different positions leading to failure of the plateletpheresis procedure. Two plateletpheresis procedures were aborted due to "Access pressure low", though the needle position was absolutely perfect. In the third event, platelet yield was not increasing even after 30 minutes from the time of initiation. It was completed after stopping the centrifuge pump which could have displaced the air bubble from the collection port...
May 2023: Curēus
https://read.qxmd.com/read/37243380/primed-for-change-the-effect-of-a-blood-prime-on-peripheral-blood-stem-cell-collection-and-accuracy-of-a-prediction-tool-in-pediatric-patients
#32
JOURNAL ARTICLE
Mahvish Q Rahim, W Scott Goebel, John Delph, Esther Soundar
Pediatric apheresis collection of peripheral blood stem cells for autologous transplantation often requires use of a blood prime. We evaluated the relationship between pre-apheresis blood CD34+ counts and final CD34+ yield with use of a blood prime. Forty patients underwent apheresis stem cell collection in a 5 year period in our hospital, of which 27 required blood priming of the apheresis machine. Despite the blood prime group having significantly higher pre-apheresis CD34+ cell counts, this group processed a relatively higher volume of blood due to a higher dilutional effect and collected significantly less than predicted CD34+ cell yield...
May 27, 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/37183555/evolving-deferral-criteria-for-blood-donation-in-france-plasma-donation-by-men-who-have-sex-with-men
#33
JOURNAL ARTICLE
Pierre Tiberghien, Sophie Lecam, Julie Huet, Lucile Malard, Tristan Tavenard, Josiane Pillonel, Claire Sauvage, Thibaut Bocquet, Cathy Bliem, Pascal Morel, Pascale Richard, Syria Laperche
BACKGROUND AND OBJECTIVES: Since the advent of AIDS, men who have sex with men (MSM) have often been deferred from blood donation. In France, quarantine plasma donation by MSM donors with the same deferral rules as for other donors was introduced in July 2016 and continued up to March 2022. At this time, MSM-specific deferral criteria were lifted for all blood or plasma donation. The donor deferral, as well as rate of infectious markers in plasma donors who would have been otherwise deferred for MSM activity, was evaluated and compared with those of the other donors during the same time period from June 2016 to March 2022...
June 2023: Vox Sanguinis
https://read.qxmd.com/read/37146295/managing-leukapheresis-in-adult-and-pediatric-patients-eligible-for-chimeric-antigen-receptor-t-cell-therapy-suggestions-from-an-italian-expert-panel
#34
JOURNAL ARTICLE
Giovanna Leone, Valentina Baldini, Stefania Bramanti, Roberto Crocchiolo, Salvatore Gattillo, Stefano Ermini, Valeria Giudice, Ivana Ferrero, Tiziana Moscato, Raffaella Milani, Maria Gozzer, Nicola Piccirillo, Cristina Tassi, Valter Tassi, Paola Coluccia
Chimeric antigen receptor (CAR) T-cell therapy relies on T cells engineered to target specific tumor antigens such as CD-19 in B-cell malignancies. In this setting, the commercially available products have offered a potential long-term cure for both pediatric and adult patients. Yet manufacturing CAR T cells is a cumbersome, multistep process, the success of which strictly depends on the characteristics of the starting material, i.e., lymphocyte collection yield and composition. These, in turn, might be affected by patient factors such as age, performance status, comorbidities, and previous therapies...
February 23, 2023: Blood Transfusion
https://read.qxmd.com/read/37070399/comparison-of-platelet-quality-and-function-across-apheresis-collection-platforms
#35
JOURNAL ARTICLE
Kimberly A Thomas, Amudan J Srinivasan, Colby McIntosh, Katelin Rahn, Scott Kelly, Lilian McGough, Skye Clayton, Samantha Perez, Alexandra Smith, Lisa Vavro, Javonn Musgrove, Ronnie Hill, Kennedy S Mdaki, James A Bynum, M Adam Meledeo, Andrew P Cap, Philip C Spinella, Kristin M Reddoch-Cardenas, Susan M Shea
BACKGROUND: Platelet concentrates (PLT) can be manufactured using a combination of apheresis collection devices and suspension media (plasma or platelet additive solution (PAS)). It is unclear how platelet quality and hemostatic function differ across the current in-use manufacturing methods in the United States. The objective of this study was therefore to compare baseline function of PLT collected using different apheresis collection platforms and storage media. STUDY DESIGN AND METHODS: PLT were collected at two sites with identical protocols (N = 5 per site, N = 10 total per group) on the MCS® + 9000 (Haemonetics; "MCS"), the Trima Accel® 7 (Terumo; "Trima"), and the Amicus Cell Separator (Fresenius Kabi, "Amicus")...
May 2023: Transfusion
https://read.qxmd.com/read/36896482/first-donor-haemovigilance-system-at-a-national-level-in-china-establishment-and-improvement
#36
JOURNAL ARTICLE
Junhong Yang, Dinrong Fan, Dongfu Xie, Xiaojie Guo, Wenqing Zhu, Tao He, Xia Huang
BACKGROUND AND OBJECTIVES: No systematic study has measured the incidence of adverse reactions (ARs) to blood donation at the national level in China before 2019. The objective of this study was to establish an effective reporting system to collect information on ARs to blood donation in China. MATERIALS AND METHODS: The status of donor haemovigilance (DHV) in blood collection facilities in China was evaluated, and an online DHV system was established to collect data on ARs to blood donation in July 2019...
March 9, 2023: Vox Sanguinis
https://read.qxmd.com/read/36893913/plateletpheresis-donor-deferral-patterns-at-a-tertiary-care-hospital-in-north-india-a-need-for-rethink-of-haemoglobin-cutoff
#37
JOURNAL ARTICLE
Himani Sharma, Kajal Khajuria, Naveen Bansal, Kusum Thakur, Ashish Sharma
INTRODUCTION: The donor deferral criteria for blood or apheresis donations are established for two main reasons: (i) to ensure the safety of the blood donor (non-maleficence); (ii) to obtain safe blood of standard quality that has therapeutic benefit for the patient (beneficence). This study was planned to assess the various causes and patterns of plateletpheresis donor deferral in our hospital and to subsequently assess whether any evidence based changes can be done in the current plateletpheresis donor deferral criteria in India to maximize the platelet donor pool without compromising donor safety...
March 7, 2023: Transfusion Clinique et Biologique: Journal de la Société Française de Transfusion Sanguine
https://read.qxmd.com/read/36739175/intermediate-dose-cyclophosphamide-and-bortezomib-for-pbsc-mobilization-in-multiple-myeloma
#38
JOURNAL ARTICLE
Aiko Sawazaki, Chiharu Sugimori, Masaki Yamaguchi, Shinji Nakao
Although the incorporation of bortezomib into induction regimens has improved, response rates in patients with multiple myeloma (MM), the role of bortezomib in the, peripheral blood stem cell (PBSC) mobilization remains unclear. We assessed the, PBSC mobilization efficacy, safety, and disease response of intermediate-dose, cyclophosphamide and bortezomib in the PBSC mobilization. Twenty-one patients with, newly diagnosed MM were enrolled in a phase II, non-randomized study that used, bortezomib (1.3 mg/m2/day on days 1, 4, 8, and 11) and intermediate-dose, cyclophosphamide (2 g/m2/day on days 2, 3) (Bor-ID-CY)...
February 1, 2023: Transfusion and Apheresis Science
https://read.qxmd.com/read/36672379/stem-cell-mobilization-with-ixazomib-and-g-csf-in-patients-with-multiple-myeloma
#39
JOURNAL ARTICLE
Selina Bühler, Dilara Akhoundova, Barbara Jeker, Myriam Legros, Katja Seipel, Michael Daskalakis, Ulrike Bacher, Thomas Pabst
(1) Background: High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard consolidation strategy for patients with newly diagnosed multiple myeloma (MM) and for a subset of patients with relapsed/refractory disease. For stem cell mobilization, G-CSF alone or in combination with chemotherapy mobilizing agents and/or plerixafor are commonly used. Ixazomib is an oral proteasome inhibitor with less neurotoxic potential, which previously showed the ability to mobilize stem cells in preclinical studies...
January 9, 2023: Cancers
https://read.qxmd.com/read/36583368/platelet-yield-and-some-donor-related-predictors-in-a-single-donor-apheresis-report-from-a-nigerian-tertiary-hospital
#40
JOURNAL ARTICLE
G C Ugwu, H C Okoye, O C Nnachi, E Nwani, O A Nnachi, I P Ezenwenyi, N I Ugwu, A E Okoye
BACKGROUND: Single-donor platelet transfusion is the preferred therapeutic option for patients with platelet insufficiency and its effectiveness is partly dependent on the yield. AIM: To determine the platelet yield and predictors of platelet yield in single-donor apheresis. MATERIALS AND METHODS: This was a five-year review of the data on single-donor apheresis using the Haemonetics Apheresis machine MCS+ at Alex Ekwueme Federal University Teaching Hospital Abakaliki Ebonyi state...
December 29, 2022: West African Journal of Medicine
keyword
keyword
165235
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.